SONN Stock: Sonnet BioTherapeutics Holdings, Inc. Stock Price, Analysis & Insights
Get live sonn stock price $3.83, comprehensive Sonnet BioTherapeutics Holdings, Inc. stock analysis, charts, news, and expert forecast. Real-time sonn stock data and investment insights.
Loading chart...
Company Overview
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Company Information
- CEO
- Raghu Rao
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
Contact Information
- Website
- https://www.sonnetbio.com
- Address
- 100 Overlook Center
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.47)
Business Model & Strategy
Sonnet BioTherapeutics Holdings, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Raghu Rao, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Sonnet BioTherapeutics Holdings, Inc. competes in the Biotechnology within the broader Healthcare. With 25.7 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Sonnet BioTherapeutics Holdings, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Sonnet BioTherapeutics Holdings, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Sonnet BioTherapeutics Holdings, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Sonnet BioTherapeutics Holdings, Inc.
- ⚠Investors should consider how Sonnet BioTherapeutics Holdings, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
25.67M
P/E Ratio
-0.56
Beta
1.47
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 25.67M market capitalization
- Trading Volume: 745.18K shares traded today
- Price Range: 52-week range of $1.08 - $19.30
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc. (SONN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 25.67M, the company represents a significant player in its market. The stock is currently trading at $3.83 with a negativedaily change of 7.81%.
The company's 13 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.56, beta of 1.47, and 52-week price range from $1.08 to $19.30when evaluating investment opportunities.
Why Invest in Sonnet BioTherapeutics Holdings, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Raghu Rao
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.